메뉴 건너뛰기




Volumn 17, Issue SUPPL. 3, 2008, Pages 16-21

Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer

Author keywords

Advanced breast cancer; Early breast cancer; Endocrine therapy; Fulvestrant

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

EID: 40949108361     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.12.004     Document Type: Article
Times cited : (21)

References (28)
  • 1
    • 20044382779 scopus 로고    scopus 로고
    • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    • Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
    • (2005) J Clin Oncol , vol.23 , pp. 619-629
    • Winer, E.P.1    Hudis, C.2    Burstein, H.J.3
  • 2
    • 33947510501 scopus 로고    scopus 로고
    • Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    • Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
    • (2007) J Clin Oncol , vol.25 , pp. 486-492
    • Coates, A.S.1    Keshaviah, A.2    Thurlimann, B.3
  • 4
    • 7444259675 scopus 로고    scopus 로고
    • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    • Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
    • (2003) N Engl J Med , vol.349 , pp. 1793-1802
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 5
    • 23444446523 scopus 로고    scopus 로고
    • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    • Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
    • (2005) Lancet , vol.366 , pp. 455-462
    • Jakesz, R.1    Jonat, W.2    Gnant, M.3
  • 6
    • 33644984327 scopus 로고    scopus 로고
    • Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial n0032
    • Ingle J.N., Suman V.J., Rowland K.M., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial n0032. J Clin Oncol 24 (2006) 1052-1056
    • (2006) J Clin Oncol , vol.24 , pp. 1052-1056
    • Ingle, J.N.1    Suman, V.J.2    Rowland, K.M.3
  • 7
    • 33846543806 scopus 로고    scopus 로고
    • Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00)
    • Perey L., Paridaens R., Hawle H., et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for clinical cancer research trial (SAKK 21/00). Ann Oncol 18 (2007) 64-69
    • (2007) Ann Oncol , vol.18 , pp. 64-69
    • Perey, L.1    Paridaens, R.2    Hawle, H.3
  • 8
    • 43249130208 scopus 로고    scopus 로고
    • Chia S, Gradishar W, Mauriac L, et al. A Double-blind, randomized, placebo-controlled trial of fulvestrant compared with exemestane after prior non steroidal aromatase inhibitor therapy in post menopausal women with hormone receptor-positive advanced breast cancer: Results from EFECT. J Clin Oncol Published online March 3, 2008, 10.1200/JCO.2007.13.5822.
    • Chia S, Gradishar W, Mauriac L, et al. A Double-blind, randomized, placebo-controlled trial of fulvestrant compared with exemestane after prior non steroidal aromatase inhibitor therapy in post menopausal women with hormone receptor-positive advanced breast cancer: Results from EFECT. J Clin Oncol Published online March 3, 2008, 10.1200/JCO.2007.13.5822.
  • 9
    • 40949122145 scopus 로고    scopus 로고
    • Activity of fulvestrant in patients with visceral metastases: results from EFECT
    • abs 2126
    • Romieu G., Bines J., and Mauriac L. Activity of fulvestrant in patients with visceral metastases: results from EFECT. Eur J Cancer Suppl 5 (2007) 222 abs 2126
    • (2007) Eur J Cancer Suppl , vol.5 , pp. 222
    • Romieu, G.1    Bines, J.2    Mauriac, L.3
  • 10
    • 0000582426 scopus 로고    scopus 로고
    • Treatment of metastatic breast cancer
    • Harris J.R. (Ed), Lippincott Williams & Wilkins, Philadelphia
    • Ellis M.J., Hayes D.F., and Lippman M. Treatment of metastatic breast cancer. In: Harris J.R. (Ed). Diseases of the breast (2000), Lippincott Williams & Wilkins, Philadelphia 749-797
    • (2000) Diseases of the breast , pp. 749-797
    • Ellis, M.J.1    Hayes, D.F.2    Lippman, M.3
  • 11
    • 0034994856 scopus 로고    scopus 로고
    • Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast
    • Kuerer H.M., Buzdar A.U., and Singletary E. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 77 (2001) 139-147
    • (2001) J Surg Oncol , vol.77 , pp. 139-147
    • Kuerer, H.M.1    Buzdar, A.U.2    Singletary, E.3
  • 12
    • 0038683988 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    • Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
    • (2003) Cancer , vol.98 , pp. 229-238
    • Robertson, J.F.1    Osborne, C.K.2    Howell, A.3
  • 13
    • 22244449598 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    • Howell A., Pippen J., Elledge R.M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104 (2005) 236-239
    • (2005) Cancer , vol.104 , pp. 236-239
    • Howell, A.1    Pippen, J.2    Elledge, R.M.3
  • 14
    • 27144494936 scopus 로고    scopus 로고
    • Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme
    • Steger G.G., Gips M., Simon S.D., et al. Fulvestrant ('Faslodex'): clinical experience from the compassionate use programme. Cancer Treat Rev 31 Suppl. 2 (2005) S10-S16
    • (2005) Cancer Treat Rev , vol.31 , Issue.SUPPL. 2
    • Steger, G.G.1    Gips, M.2    Simon, S.D.3
  • 15
    • 33748110786 scopus 로고    scopus 로고
    • Intentional and non-intentional non-adherence to medication amongst breast cancer patients
    • Atkins L., and Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42 (2006) 2271-2276
    • (2006) Eur J Cancer , vol.42 , pp. 2271-2276
    • Atkins, L.1    Fallowfield, L.2
  • 16
    • 27144456229 scopus 로고    scopus 로고
    • Incidence of polypharmacy in patients with breast cancer
    • Robertson J.F.R. Incidence of polypharmacy in patients with breast cancer. Breast 14 Suppl. 1 (2005) S39
    • (2005) Breast , vol.14 , Issue.SUPPL. 1
    • Robertson, J.F.R.1
  • 17
    • 31544469565 scopus 로고    scopus 로고
    • Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
    • Fallowfield L., Atkins L., Catt S., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17 (2006) 205-210
    • (2006) Ann Oncol , vol.17 , pp. 205-210
    • Fallowfield, L.1    Atkins, L.2    Catt, S.3
  • 18
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • ATAC Trialists' Group
    • ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
    • (2005) Lancet , vol.365 , pp. 60-62
  • 19
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • Thurlimann B., Keshaviah A., Coates A., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
    • Thurlimann, B.1    Keshaviah, A.2    Coates, A.3
  • 20
    • 33846545851 scopus 로고    scopus 로고
    • Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    • Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
    • (2007) Lancet , vol.369 , pp. 559-570
    • Coombes, R.C.1    Kilburn, L.S.2    Snowdon, C.F.3
  • 21
    • 0038683988 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials
    • Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 98 (2003) 229-238
    • (2003) Cancer , vol.98 , pp. 229-238
    • Robertson, J.F.1    Osborne, C.K.2    Howell, A.3
  • 22
    • 85074743634 scopus 로고    scopus 로고
    • Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant
    • Robertson J.F.R., Agrawal A., Hannon R.A., Cheung K.L., and Eastell R. Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant. Breast 16 (2007) S53
    • (2007) Breast , vol.16
    • Robertson, J.F.R.1    Agrawal, A.2    Hannon, R.A.3    Cheung, K.L.4    Eastell, R.5
  • 23
    • 0035884408 scopus 로고    scopus 로고
    • Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
    • Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61 (2001) 6739-6746
    • (2001) Cancer Res , vol.61 , pp. 6739-6746
    • Robertson, J.F.1    Nicholson, R.I.2    Bundred, N.J.3
  • 24
    • 0037102126 scopus 로고    scopus 로고
    • Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
    • Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
    • (2002) J Clin Oncol , vol.20 , pp. 3386-3395
    • Osborne, C.K.1    Pippen, J.2    Jones, S.E.3
  • 25
    • 0037102121 scopus 로고    scopus 로고
    • Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    • Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
    • (2002) J Clin Oncol , vol.20 , pp. 3396-3403
    • Howell, A.1    Robertson, J.F.R.2    Quaresma Albano, J.3
  • 26
    • 34548241775 scopus 로고    scopus 로고
    • Fulvestrant (Faslodex) how to make a good drug better
    • Robertson J.F. Fulvestrant (Faslodex) how to make a good drug better. Oncologist 12 (2007) 774-784
    • (2007) Oncologist , vol.12 , pp. 774-784
    • Robertson, J.F.1
  • 27
    • 0042232592 scopus 로고    scopus 로고
    • Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
    • Martin L.-A., Farmer I., Johnston S.R.D., et al. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278 (2003) 30458-30468
    • (2003) J Biol Chem , vol.278 , pp. 30458-30468
    • Martin, L.-A.1    Farmer, I.2    Johnston, S.R.D.3
  • 28
    • 20444448539 scopus 로고    scopus 로고
    • Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
    • Jelovac D., Macedo L., Goloubeva O.G., Handratta V., and Brodie A.M. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65 (2005) 5439-5444
    • (2005) Cancer Res , vol.65 , pp. 5439-5444
    • Jelovac, D.1    Macedo, L.2    Goloubeva, O.G.3    Handratta, V.4    Brodie, A.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.